Cargando…

Genetic variants in the Folic acid Metabolic Pathway Genes predict outcomes of metastatic Colorectal Cancer patients receiving first-line Chemotherapy

Background: The association between genetic variants in the folic acid metabolic pathway genes and survival, as well as the responses to chemotherapy of metastatic colorectal cancer (mCRC) patients has not been reported. Methods: The association between genetic variants in the folic acid metabolic p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lu, Li, Shuwei, Yuan, Ming, Ma, Ling, Lin, Yu, Zhu, Weiyou, Du, Haina, Wang, Meilin, Chen, Tao, Zhu, Lingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545690/ https://www.ncbi.nlm.nih.gov/pubmed/33046972 http://dx.doi.org/10.7150/jca.44580

Ejemplares similares

Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials
por: Qin, Tingting, et al.
Publicado: (2015)

Genetic variants in autophagy-related gene ATG2B predict the prognosis of colorectal cancer patients receiving chemotherapy
por: Yu, Ting, et al.
Publicado: (2022)

Functional genetic variant of HSD17B12 in the fatty acid biosynthesis pathway predicts the outcome of colorectal cancer
por: Lin, Yu, et al.
Publicado: (2020)

Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population
por: Li, Shuwei, et al.
Publicado: (2016)

Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population
por: Du, Haina, et al.
Publicado: (2014)

Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer
por: Ren, Anjing, et al.
Publicado: (2019)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

Genetic variants in RNA m(5)C modification genes associated with survival and chemotherapy efficacy of colorectal cancer
por: Chen, Silu, et al.
Publicado: (2022)

Genetic variant in miR‐21 binding sites is associated with colorectal cancer risk
por: Xie, Lisheng, et al.
Publicado: (2018)

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
por: Díaz-Rubio, Eduardo, et al.
Publicado: (2012)

The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-Line Chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2019)

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer
por: Zhao, Jing, et al.
Publicado: (2013)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment
por: Schuurhuizen, Claudia S. E. W., et al.
Publicado: (2019)

Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer
por: Fisch, Michael J, et al.
Publicado: (2020)

Genetic Variant rs7758229 in 6q26–q27 Is Not Associated with Colorectal Cancer Risk in a Chinese Population
por: Zhu, Lingjun, et al.
Publicado: (2013)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
por: Antoun, Sami, et al.
Publicado: (2019)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Retrospective analysis of the efficacy of cytokine‐induced killer cell immunotherapy combined with first‐line chemotherapy in patients with metastatic colorectal cancer
por: Pan, Qiu‐Zhong, et al.
Publicado: (2020)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
por: Paré, L, et al.
Publicado: (2008)

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
por: Paré, L, et al.
Publicado: (2009)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
por: Hwang, Jun-Eul, et al.
Publicado: (2011)

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer
por: de Liaño, A G, et al.
Publicado: (2014)

A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy()
por: Wang, Jin, et al.
Publicado: (2016)

Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2003)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study
por: Maddalena, Chiara, et al.
Publicado: (2021)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy
por: Jiang, Jinling, et al.
Publicado: (2019)

Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer
por: Li, Shuwei, et al.
Publicado: (2017)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
por: Kou, Furong, et al.
Publicado: (2016)

Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
por: Wang, Jin, et al.
Publicado: (2020)

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment
por: Gürsoy, Pınar, et al.
Publicado: (2022)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lr79dvh8ma9n4ve73atvg8sa9p